Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Billion to One

BillionToOne is a molecular diagnostics company with a mission to make molecular diagnostics more accurate, efficient... read more Featured Products: More products

Download Mobile App




Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy

By LabMedica International staff writers
Posted on 03 Mar 2025

In the United States, approximately 15% of pregnant individuals are RhD-negative. More...

However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary. Now, a non-invasive prenatal test (NIPT) for determining fetal RhD status has demonstrated 100% accuracy in a large clinical study, enabling healthcare providers to use the results to guide RhoGAM administration.

The study demonstrated that BillionToOne’s (Menlo Park, CA, USA) proprietary next-generation sequencing (NGS) combined with Quantitative Counting Template (QCT) technology provides definitive results with perfect accuracy. The study included challenging variants, such as RHDѰ and RHD-C-DE, which are often omitted in other studies, ensuring a true reflection of clinical performance. The test achieved 100% sensitivity, specificity, positive predictive value, and negative predictive value across 401 pregnancies when compared to neonatal RhD serology, considered the gold standard. One of the standout features of BillionToOne's technology is its ability to detect difficult RhD variants, a capability that sets it apart from other commercial tests.

The study also demonstrated 100% accuracy in identifying fetal RHDѰ variants, which occur in approximately 25% of Black Rh-negative individuals, as well as RHD-CE-D hybrid variants. Many other commercially available fetal RhD NIPTs cannot detect the fetal RhD status in cases where these variants are present, thus limiting the test's applicability in the broader obstetric population. This feature is particularly critical for ensuring accurate testing across diverse populations, especially in the US. The research confirms the clinical validity of the test, with healthcare providers already using the results to guide RhoGAM administration. Over time, as clinicians grew more confident in the test's accuracy, there was a noticeable reduction in unnecessary RhoGAM administration for pregnancies with RhD-negative fetuses.

This marks BillionToOne's third peer-reviewed publication on its fetal antigen assay and the second published in The Journal of Obstetrics and Gynecology. This latest publication follows a recent update from the American College of Obstetricians and Gynecologists (ACOG), which supported the use of non-invasive cell-free DNA screening for fetal RhD, especially during RhoGAM shortages and as an alternative in alloimmunized pregnancies when amniocentesis is declined. ACOG’s updates referenced BillionToOne's prior studies.

"By accurately identifying fetal RhD status, we can avoid unnecessary RhoGAM administration in approximately 40% of patients carrying RhD-negative fetuses," said Dr. Julio Mateus Nino, MD, Maternal & Fetal Medicine, first author of the study. "BillionToOne's QCT technology also provides critical information for patients with RhD alloimmunization, giving physicians the tools to guide antenatal management based on actual fetal genotype rather than assumption. This is a meaningful advancement in personalized prenatal care that benefits both patients and healthcare systems."

Related Links:
BillionToOne


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gel Cards
DG Gel Cards
New
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.